Department of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysore, Karnataka, India
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo‑controlled, phase 2 trial. Lancet 2020;396:479‑88. 2. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdO×1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single‑blind, randomised controlled trial. Lancet 2020;396:467‑78. 3. Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI-P, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): A systematic review. J Clin Med 2020;9:623. 4. Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun 2020;11:1‑13.
5. Jamrozik E, Selgelid MJ. COVID-19 human challenge studies: Ethical issues. Lancet Infect Dis 2020;3099:18‑20. Available from: http://dx.doi.org/10.1016/S1473‑3099(20)30438‑2. [Last accessed on 2020 Aug 01].
